» Articles » PMID: 33853869

An HIV Diagnostic Testing Algorithm Using the Cobas HIV-1/HIV-2 Qualitative Assay for HIV Type Differentiation and Confirmation

Abstract

Human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2) diagnostic testing algorithms recommended by the Centers for Disease Control involve up to three tests and rely mostly on detection of viral antigen and host antibody responses. HIV-1 p24 antigen/HIV-1/HIV-2 antibody-reactive specimens are confirmed with an immunochromatographic HIV-1/HIV-2 antibody differentiation assay, and negative or indeterminate results from the differentiation assay are resolved by an HIV-1-specific nucleic acid amplification test (NAT). The performance of a proposed alternative algorithm using the cobas HIV-1/HIV-2 qualitative NAT as the differentiation assay was evaluated in subjects known to be infected with HIV-1 ( = 876) or HIV-2 ( = 139), at low ( = 6,017) or high ( = 1,020) risk of HIV-1 infection, or at high-risk for HIV-2 infection ( = 498) (study A). The performance of the cobas HIV-1/HIV-2 qualitative test was also evaluated by comparison to an HIV-1 or HIV-2 alternative NAT (study B). The HIV-1 and HIV-2 overall percent agreements (OPA) in study A ranged from 95% to 100% in all groups. The positive percent agreements (PPA) for HIV-1 and HIV-2 were 100% (876/876) and 99.4% (167/168), respectively, for known positive groups. The negative percent agreement in the HIV low-risk group was 100% for both HIV-1 and HIV-2. In study B, the HIV-1 and HIV-2 OPA ranged from 99% to 100% in all groups evaluated ( = 183 to 1,030), and the PPA for HIV-1 and HIV-2 were 100% and 99.5%, respectively, for known positive groups. The cobas HIV-1/HIV-2 qualitative assay can discriminate between HIV-1 and HIV-2 based on HIV RNA and can be included in an alternative diagnostic algorithm for HIV.

Citing Articles

Incidence and Risks of HIV Infection, Medication Options, and Adverse Effects in Accidental Needle Stick Injuries: A Narrative Review.

Abadie R, Brown E, Campbell J, Alvarez I, Allampalli V, Ahmadzadeh S Cureus. 2024; 16(1):e51521.

PMID: 38304675 PMC: 10831193. DOI: 10.7759/cureus.51521.


Reflex Human Immunodeficiency Virus (HIV) Type 1 RNA Testing Enables Timely Differentiation of False-Positive Results From Acute HIV Infection.

Kaperak C, Eller D, Devlin S, Hall A, Schmitt J, Friedman E Open Forum Infect Dis. 2024; 11(1):ofad629.

PMID: 38269050 PMC: 10807991. DOI: 10.1093/ofid/ofad629.


Efficacy and Safety of Two-Drug Regimens That Are Approved from 2018 to 2022 for the Treatment of Human Immunodeficiency Virus (HIV) Disease and Its Opportunistic Infections.

Sivanandy P, Ng Yujie J, Chandirasekaran K, Hong Seng O, Azhari Wasi N Microorganisms. 2023; 11(6).

PMID: 37374953 PMC: 10302027. DOI: 10.3390/microorganisms11061451.

References
1.
Montesinos I, Eykmans J, Delforge M . Evaluation of the Bio-Rad Geenius HIV-1/2 test as a confirmatory assay. J Clin Virol. 2014; 60(4):399-401. DOI: 10.1016/j.jcv.2014.04.025. View

2.
Gottlieb G, Raugi D, Smith R . 90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2. Lancet HIV. 2018; 5(7):e390-e399. DOI: 10.1016/S2352-3018(18)30094-8. View

3.
Ginocchio C, Wang X, Kaplan M, Mulligan G, Witt D, Romano J . Effects of specimen collection, processing, and storage conditions on stability of human immunodeficiency virus type 1 RNA levels in plasma. J Clin Microbiol. 1997; 35(11):2886-93. PMC: 230081. DOI: 10.1128/jcm.35.11.2886-2893.1997. View

4.
Okulicz J, Lambotte O . Epidemiology and clinical characteristics of elite controllers. Curr Opin HIV AIDS. 2011; 6(3):163-8. DOI: 10.1097/COH.0b013e328344f35e. View

5.
Amellal B, Katlama C, Calvez V . Evaluation of the use of dried spots and of different storage conditions of plasma for HIV-1 RNA quantification. HIV Med. 2007; 8(6):396-400. DOI: 10.1111/j.1468-1293.2007.00484.x. View